Incretins: The Unsung Heroes of Heart Health in Diabetes?
"Explore how incretin-based therapies are revolutionizing diabetes care with surprising cardiovascular benefits."
Cardiovascular disease (CVD) remains a leading cause of death for individuals with diabetes mellitus (DM). While the link between diabetes and heart issues is well-established, traditional treatments for managing blood sugar haven't always translated into better cardiovascular outcomes. This has led researchers to explore new therapeutic avenues.
Enter incretins, a group of gut-derived hormones that are gaining attention not only for their role in glucose regulation but also for their potential heart-protecting properties. These hormones, which include glucagon-like peptide-1 (GLP-1), stimulate insulin release and suppress glucagon, effectively managing blood sugar levels. But their benefits appear to extend far beyond glucose control.
This article examines the exciting research surrounding incretins and their impact on cardiovascular health. We'll delve into how these agents work, the specific benefits they offer to the heart, and what the future holds for incretin-based therapies in diabetes care.
Diabetes Burden and Incretin Evidence
The CDC’s National Diabetes Statistics Report provides current information on diabetes incidence, prevalence, complications, death, and costs in the United States. The report also covers prediabetes, risk factors for complications, and acute and long-term complications, helping guide prevention and control efforts. Reviews of incretin therapies, including evidence from the SURPASS and SURMOUNT trials, report strong effects on glycemic control and weight loss, while also warning about inappropriate insulin discontinuation in insulin-dependent people with diabetes.
From Insulin to Incretin Modulation
Incretins are gastrointestinal hormones that enhance insulin secretion from pancreatic β-cells, with GIP and GLP-1 identified as the major incretins. Incretin-mediated insulin stimulation contributes to lowering postprandial blood-glucose levels. Earlier work described progressive deterioration of the incretin system as a component of type 2 diabetes pathophysiology, supporting therapies that modulate this system, while insulin treatment for type 1 diabetes can be expensive or complex.
How Do Incretins Protect the Heart?
Incretin-based therapies, including GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, work by mimicking or prolonging the action of natural incretin hormones. While their glucose-regulating effects are well-known, their potential cardiovascular benefits are multifaceted:
- Reducing Inflammation: Incretins possess anti-inflammatory actions, which can help stabilize atherosclerotic plaques and prevent them from rupturing, a major cause of heart attacks and strokes.
- Preventing Atherosclerosis: These agents exhibit anti-atherogenic properties, meaning they can help prevent the formation of new plaques and slow the progression of existing ones.
- Improving Lipid Profile: Incretins can positively impact blood lipid levels, reducing triglycerides and increasing high-density lipoprotein (HDL) cholesterol (the "good" cholesterol).
- Lowering Blood Pressure: Some studies suggest that incretins can help lower blood pressure, reducing the strain on the cardiovascular system.
Emerging Cardiovascular Directions
Recent research links metabolic syndrome with type 2 diabetes, coronary heart disease, stroke, and other cardiovascular events. In laboratory research using H9c2 cardiomyoblasts, GLP-1(9-36) was identified as a potential target for limiting oxidative stress and apoptosis through PI3K/Akt/nitric oxide synthase signaling. In diabetic rats, direct delivery of recombinant GLP-1 produced the lowest reported carotid intima-media ratio, 1.58 ± 0.48, compared with 2.80 ± 0.51 for exenatide treatment and 3.73 ± 0.90 for the control group.
Limits, Risks, and Study Boundaries
A review of incretin cardiovascular effects reports that cardiovascular disease and stroke account for 75% of deaths among patients with diabetes mellitus. Clinical evidence can also have restricted generalizability: one study excluded people with diabetic ketoacidosis, significant liver or renal disease, pharmacologically treated congestive heart failure, recent coronary intervention, unstable angina, and those older than 80 years. In addition, glucagon receptor agonists may appear counterintuitive in diabetes because glucagon raises glucose, although glucagon can also inhibit food intake and promote weight loss through glucagon and GLP-1 receptors.
Comparing Incretins and Insulin
In type 2 diabetes, one source reports that the incretin response is decreased. Incretin therapies, including GLP-1 receptor agonists and DPP-4 inhibitors, enhance the body’s insulin response to food, whereas bolus insulin directly replaces mealtime insulin. A 26-week randomized controlled trial compared once-daily semaglutide with liraglutide and placebo in patients with type 2 diabetes inadequately controlled by diet and exercise, with or without metformin.
The Future of Incretins in Cardiovascular Care
While the research on incretins and cardiovascular health is promising, larger randomized controlled trials are needed to fully understand the clinical implications of these findings. However, the existing evidence suggests that incretin-based therapies may offer a valuable tool in the fight against cardiovascular disease in individuals with diabetes. As research continues, we can expect a clearer picture of how to best utilize these agents for optimal heart health.
Pregnancy Evidence and Expert Consensus
A September 2026 Lancet publication is identified as a systematic review, meta-analysis, and international expert consensus statement on GLP-1 receptor agonist-based therapies. Its scope includes preconception, pregnancy, and postnatal use in women with type 1 diabetes, type 2 diabetes, or gestational diabetes. The source title indicates that expert guidance is being developed across these reproductive and diabetes contexts.
From Trials to Everyday Care
Incretin-based therapies have transformed the management of obesity and type 2 diabetes, but the extent to which substantial weight loss and glycemic improvements from pivotal randomized controlled trials translate to clinical populations remains uncertain. A 2026 narrative review compares randomized-trial meta-analyses with real-world effectiveness studies because clinicians, health systems, and policymakers continue to question that translation. Across four SURE studies of once-weekly semaglutide, 1,212 patients were included in the post hoc analysis, with a mean treatment duration of 30.8 ± 9.6 weeks; the mean age was 60.1 years and mean diabetes duration was 12.2 years.